熱門資訊> 正文
Biomea Fusion sinks 25%, prices $40M stock offering
2025-06-18 14:39
- Clinical-stage diabetes and obesity company, Biomea Fusion (NASDAQ:BMEA) priced its previously announced underwritten public offering of 19.45M shares and accompanying warrants to buy the same number of shares.
- The underwriters have a 30-day option to purchase up to an additional 3M shares.
- The combined offering price of each share and accompanying common stock warrant is $2.00. The combined offering price of each pre-funded warrant and accompanying warrant is $1.9999.
- The gross proceeds are expected to be ~$40 million.
- The offering is expected to close on June 20, 2025.
- the stock price dropped about 25% on Tuesday during after market hours of trading.
More on Biomea Fusion
- Biomea Fusion launches public offering of stock and warrants; shares down 23%
- Biomea Fusion appoints Mick Hitchcock to succeed Thomas Butler as interim CEO
- Seeking Alpha’s Quant Rating on Biomea Fusion
- Historical earnings data for Biomea Fusion
- Financial information for Biomea Fusion
推薦文章
美股機會日報 | 凌晨3點！美聯儲將公佈1月貨幣政策會議紀要，納指期貨漲近0.5%；13F大曝光！巴菲特連續三季減持蘋果
美股機會日報 | 阿里發佈千問3.5！性能媲美Gemini 3；馬斯克稱Cybercab將於4月開始生產
港股周報 | 中國大模型「春節檔」打響！智譜周漲超138%；鉅虧超230億！美團周內重挫超10%
一周財經日曆 | 港美股迎「春節+總統日」雙假期！萬億零售巨頭沃爾瑪將發財報
從軟件到房地產，美國多板塊陷入AI恐慌拋售潮
Meta計劃為智能眼鏡添加人臉識別技術
危機四伏，市場卻似乎毫不在意
財報前瞻 | 英偉達Q4財報放榜在即！高盛、瑞銀預計將大超預期，兩大關鍵催化將帶來意外驚喜？
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
